AbbVie
ABBV
2,367 hedge funds and large institutions have $106B invested in AbbVie in 2020 Q3 according to their latest regulatory filings, with 110 funds opening new positions, 1,064 increasing their positions, 912 reducing their positions, and 130 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 1,064 | Existing positions reduced: 912
1.17% less ownership
Funds ownership: 69.92% → 68.75% (-1.2%)
2% less funds holding
Funds holding: 2,412 → 2,367 (-45)
12% less capital invested
Capital invested by funds: $121B → $106B (-$14.7B)
15% less first-time investments, than exits
New positions opened: 110 | Existing positions closed: 130
29% less call options, than puts
Call options by funds: $1.35B | Put options by funds: $1.89B
39% less funds holding in top 10
Funds holding in top 10: 197 → 121 (-76)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Berkshire Hathaway
Omaha,
Nebraska
|
+$2B |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$323M |
| 3 |
Barclays
London,
United Kingdom
|
+$279M |
| 4 |
Morgan Stanley
New York
|
+$122M |
| 5 |
DKCM
Davidson Kempner Capital Management
New York
|
+$114M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$851M |
| 2 |
Renaissance Technologies
New York
|
-$523M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$499M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$287M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$278M |
ABBV Hedge Fund Activity: Q3 2020 in Review
2,367 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2020, worth a combined $106B — down 12% from $121B a quarter earlier.
Sellers outnumbered buyers: 130 funds closed out of ABBV and 110 opened new positions — a net loss of 20 holders — while 912 trimmed existing stakes and 1,064 added.
The largest buyer was Berkshire Hathaway, opening a new position worth an estimated $2B. The largest seller was T. Rowe Price Associates, cutting an estimated $851M.
- 2,367 institutional investors held AbbVie (ABBV) as of Q3 2020, down from 2,412 in Q2 2020.
- Funds reported $106B of AbbVie stock for Q3 2020, down 12% quarter-over-quarter.
- 110 funds opened new AbbVie positions in Q3 2020 and 130 closed out, a net change of -20 holders.
- The largest AbbVie buyer in Q3 2020 was Berkshire Hathaway, an estimated $2B added.
- The largest AbbVie seller in Q3 2020 was T. Rowe Price Associates, an estimated $851M sold.
Based on aggregated 13F filings for Q3 2020.